Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 6:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 4,205 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Injectable Placebo Clear all
Terminated Phase 3 Interventional Results available

Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

NCT03443973
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Gantenerumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
975 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
47
States / cities
Phoenix, Arizona • Sun City, Arizona • Fayetteville, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 18, 2026, 6:57 AM EDT
Withdrawn Phase 2 Interventional

A Study of JNJ-64304500 in Participants With Alopecia Areata

NCT04740970
View directory record Official record
Conditions
Alopecia Areata
Interventions
JNJ-64304500, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Tampa, Florida • Plainfield, Indiana • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 18, 2026, 6:57 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)

NCT04569786
View directory record Official record
Conditions
Coronavirus Disease (COVID-19)
Interventions
V590, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
7
States / cities
Tempe, Arizona • Miami, Florida • South Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 18, 2026, 6:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers

NCT01590446
View directory record Official record
Conditions
Achondroplasia
Interventions
BMN 111, Normal Saline
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
22 Years to 45 Years · Male only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Oct 18, 2026, 6:57 AM EDT
Completed Phase 3 Interventional Results available

Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2

NCT01763827
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe
Biological · Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
47
States / cities
Birmingham, Alabama • Chandler, Arizona • Little Rock, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 18, 2026, 6:57 AM EDT
Completed Phase 1 Interventional

Study to Evaluate the Effects of RM-131 in Patients With Chronic Constipation

NCT02137642
View directory record Official record
Conditions
Chronic Constipation
Interventions
RM-131, Placebo
Drug
Lead sponsor
Motus Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Oct 18, 2026, 6:57 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma

NCT00267202
View directory record Official record
Conditions
Allergic Asthma
Interventions
Placebo, Omalizumab, Immunotherapy
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 55 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Oct 18, 2026, 6:57 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

NCT05721573
View directory record Official record
Conditions
Inclusion Body Myositis
Interventions
ABC008
Drug
Lead sponsor
Abcuro, Inc.
Industry
Eligibility
40 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
34
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 18, 2026, 6:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate a Skeletal-muscle Microbiopsy Technique With Dynamic Proteomic Measurement in Healthy Male Volunteers

NCT01962454
View directory record Official record
Conditions
Cachexia
Interventions
Deuterated Water, Testosterone enanthate, Placebo to match testosterone enanthate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
60 Years to 75 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 18, 2026, 6:57 AM EDT
Enrolling by invitation Phase 4 Interventional

Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy

NCT06191094
View directory record Official record
Conditions
Diabetic Retinopathy, Vitreous Hemorrhage Due to Diabetes Mellitus
Interventions
Faricimab Injection, sham treatment
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 18, 2026, 6:57 AM EDT
Completed Phase 1 Interventional

NMDA Receptor Modulation for Hyperarousal in PTSD

NCT03166501
View directory record Official record
Conditions
Depression, Post Traumatic Stress Disorder
Interventions
Lanicemine, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Oct 18, 2026, 6:57 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

NCT04199689
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
9vHPV Vaccine, Placebo (Saline for Injection)
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
20 Years to 45 Years · Male only
Enrollment
6,033 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
32
States / cities
Northridge, California • Rialto, California • Simi Valley, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 18, 2026, 6:57 AM EDT
Completed Phase 2 Interventional Results available

Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

NCT01490450
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Placebo matching BMS-945429, BMS-945429
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
San Diego, California • Denver, Colorado • Trumbull, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 18, 2026, 6:57 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis

NCT03025542
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Bexley, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 18, 2026, 6:57 AM EDT
Completed Phase 1 Interventional

Effects of Synvisc on Cartilage in Knee Osteoarthritis (OA)

NCT00949494
View directory record Official record
Conditions
Osteoarthritis
Interventions
Synvisc
Device
Lead sponsor
Endeavor Health
Other
Eligibility
40 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 18, 2026, 6:57 AM EDT
Completed Phase 2 Interventional Results available

The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease

NCT00755222
View directory record Official record
Conditions
Peyronie's Disease
Interventions
AA4500, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
Burbank, California • Middlebury, Connecticut • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 18, 2026, 6:57 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)

NCT02453256
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Placebo, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
16
States / cities
El Cajon, California • Fullerton, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 18, 2026, 6:57 AM EDT
Completed Not applicable Interventional Results available

Transversus Abdominis Plane (TAP) Block Laparoscopic Hysterectomy

NCT01074229
View directory record Official record
Conditions
Postoperative Pain
Interventions
Placebo, Drug .5% Ropivacaine, 20 cc of 0.25% ropivacaine
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Oct 18, 2026, 6:57 AM EDT
Terminated Phase 3 Interventional Results available

GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases

NCT01257802
View directory record Official record
Conditions
Lupus Erythematosus, Systemic, Systemic Vasculitis, Isolated Angiitis of Central Nervous System, Lung Disease With Systemic Sclerosis, Lung Disease Interstitial Diffuse
Interventions
depot leuprolide acetate 3.75 mg, Placebo
Drug
Lead sponsor
Joseph Mccune
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Ann Arbor, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 18, 2026, 6:57 AM EDT
Completed Phase 2 Interventional Results available

Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study

NCT03682965
View directory record Official record
Conditions
Allergic Rhinitis Due to Tree Pollen, Allergic Conjunctivitis, Allergic Rhinoconjunctivitis
Interventions
Intra-lymphatic allergenic extract, Intra-lymphatic placebo
Biological
Lead sponsor
Christopher Thompson, MD
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Austin, Texas • Grapevine, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 18, 2026, 6:57 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab

NCT06241573
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Spesolimab, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Fountain Valley, California • Los Angeles, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 18, 2026, 6:57 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants

NCT01318694
View directory record Official record
Conditions
Hepatitis C
Interventions
Alisporivir, Peginterferon alfa-2a, Ribavirin, ALV Placebo
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
32
States / cities
Beverly Hills, California • Oakland, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 18, 2026, 6:57 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia

NCT01469039
View directory record Official record
Conditions
Schizophrenia
Interventions
ALKS 9072, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
26
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Cerritos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 18, 2026, 6:57 AM EDT
Completed Phase 3 Interventional

To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia

NCT05852431
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Pegozafermin, Placebo
Drug
Lead sponsor
89bio, Inc.
Industry
Eligibility
22 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
73
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 18, 2026, 6:57 AM EDT